Inhibrx Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Cash & Equivalents	277.92	273.87	131.3	128.66	11.54	2.1
Cash & Cash Equivalents	277.92	273.87	131.3	128.66	11.54	2.1
Cash Growth	1.48%	108.58%	2.05%	1014.94%	448.74%	-
Receivables	0.78	0.26	0.88	0.62	0.44	0.69
Other Current Assets	16.66	6.37	6.93	2.89	3.58	2.86
Total Current Assets	295.36	280.49	139.11	132.17	15.56	5.66
Property, Plant & Equipment	9.37	7.22	9.49	11.32	10.68	2.59
Other Long-Term Assets	3.16	3.16	1.85	0.25	0.25	1.73
Total Long-Term Assets	12.54	10.38	11.34	11.57	10.93	4.33
Total Assets	307.89	290.88	150.45	143.74	26.49	9.98
Accounts Payable	10.95	8.33	9.13	13.46	3.12	6.53
Deferred Revenue	0	0.17	2.14	3.82	8.94	0
Current Debt	2.06	1.86	1.67	1.5	4.67	5.93
Other Current Liabilities	43.3	17.22	9.51	12.62	3.85	3.72
Total Current Liabilities	56.31	27.58	22.45	31.4	20.57	16.18
Long-Term Debt	208.08	205.24	75.5	35.95	37.07	3.56
Other Long-Term Liabilities	0	0	0.11	0.92	2.92	0.36
Total Long-Term Liabilities	208.08	205.24	75.61	36.87	39.98	3.93
Total Liabilities	264.39	232.82	98.07	68.27	60.55	20.11
Total Debt	210.14	207.1	77.18	37.45	41.73	9.49
Debt Growth	1.47%	168.35%	106.06%	-10.25%	339.57%	-
Retained Earnings	-613.73	-372.37	-227.15	-145.38	-69.26	-17.86
Shareholders' Equity	43.5	58.06	52.38	75.47	-93.57	-57.64
Net Cash / Debt	67.78	66.76	54.12	91.21	-30.19	-7.39
Net Cash / Debt Growth	1.53%	23.35%	-40.66%	-	-	-
Net Cash Per Share	1.44	1.66	1.42	3.61	-1.66	-0.41
Working Capital	239.05	252.92	116.66	100.77	-5.01	-10.53
Book Value Per Share	0.92	1.45	1.38	2.99	-5.15	-3.17

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).